Suscribirse

Cigarette Smoking and Structural Brain Deficits in Patients With Atrial Fibrillation - 22/01/25

Doi : 10.1016/j.amjcard.2024.11.008 
Raffaele Peter, MD a, b, Stefanie Aeschbacher, PhD a, b, Rebecca E. Paladini, PhD a, b, Michael Coslovsky, PhD a, b, c, Philipp Krisai, MD a, b, Adrian Schweigler, MD a, b, Tobias Reichlin, MD d, Nicolas Rodondi, MD e, f, Andreas Müller, MD g, Moa Haller, MD e, h, Merit Röhl, MD d, Annina Stauber, MD g, i, Tim Sinnecker, MD j, Leo H. Bonati, MD k, l, Thilo Burkard, MD b, m, David Conen, MD n, Stefan Osswald, MD a, b, Michael Kühne, MD a, b, Christine S. Zuern, MD a, b,
a Cardiovascular Research Institute Basel, University Hospital Basel, University of Basel, Basel, Switzerland 
b Cardiology Division, Department of Medicine, University Hospital Basel, University of Basel, Basel, Switzerland 
c Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland 
d Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland 
e Institute of Primary Health Care, University of Bern, Bern, Switzerland 
f Department of General Internal Medicine, Inselspital, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland 
g Department of Cardiology, Triemli Hospital Zürich, Zürich, Switzerland 
h Faculty of Medicine, University of Bern, Bern, Switzerland 
i Department of Cardiology, Kantonsspital Winterthur, Winterthur, Switzerland 
j Medical Image Analysis Center (MIAC) and Department of Biomedical Engineering, University of Bern, Bern, Switzerland 
k Department of Neurology and Stroke Center, University of Basel, Basel, Switzerland 
l Research Department, Reha Rheinfelden, Rheinfelden, Switzerland 
m Medical Outpatient Department and Hypertension Clinic, ESH Hypertension Centre of Excellence, University Hospital Basel, Basel, Switzerland 
n Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada 

Corresponding author.

Resumen

Cigarette smoking and atrial fibrillation (AF) are associated with impaired brain health. We investigated the association between smoking habits and brain lesions and volume in patients with AF. In patients with AF from a multicenter cohort study, we assessed smoking status (never, ex-, active), number of cigarettes smoked per day, smoking duration (years), pack-years, and time since smoking cessation. On brain magnetic resonance imaging, the prevalence and volumes of white matter lesions (WML) and small noncortical infarcts, and the volumes of gray matter and white matter were evaluated. Logistic and linear regression analyses were used to analyze the association between smoking habits and brain lesions and volumes. A total of 1,728 patients were enrolled (mean age 72.6 years, 27.5% female); 7.5% were active smokers; 48.5% were ex-smokers, and 44% had never smoked. We found linear associations of number of cigarettes smoked per day, pack-years, and older age at smoking cessation with reduced gray matter volume (p for linear trend <0.01, 0.02, and 0.01, respectively). Patients with a smoking duration in the second and third tertile had a greater risk for WML Fazekas ≥2 (odds ratio 1.86, 95% confidence interval 1.29 to 2.69, p <0.01 and 1.47 [1.02 to 2.12], p = 0.04), and exhibited larger WML volumes. Patients who had stopped smoking ≥16 years before enrollment were less likely to have small noncortical infarcts (odds ratio 0.46, 0.25 to 0.88, p = 0.02) and had smaller WML volumes (β: −0.451 mm3, −0.8 to −0.11, p = 0.01). In conclusion, smoking intensity and time since smoking cessation were associated with the presence and volume of brain lesions and with brain volumes in patients with AF.

El texto completo de este artículo está disponible en PDF.

Keywords : atrial fibrillation, brain deficits, smoking, smoking cessation


Esquema


 The Swiss Atrial Fibrillation study is supported by grants of the Swiss National Science Foundation (Wildhainweg 3, 3001 Bern, CH), Grant numbers 33CS30_148474, 33CS30_177520, 32473B_176178, and 32003B_197524, the Swiss Heart Foundation (Dufourstrasse 30 3005 Bern), the Foundation for Cardiovascular Research Basel (Basel Spitalstr. 2 CH-4056 Basel, CH) , and the University of Basel (Petersplatz 1, 4001 Basel Switzerland).


© 2024  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 237

P. 72-78 - février 2025 Regresar al número
Artículo precedente Artículo precedente
  • Abbreviated Duke Activity Status Index for Risk Stratification in Heart Failure
  • Silvio Nunes Augusto, Yuping Wu, Thanat Chaikijurajai, Stanley L. Hazen, W. H. Wilson Tang
| Artículo siguiente Artículo siguiente
  • A Multicenter Evaluation of the Impact of Therapies on Deep Learning-Based Electrocardiographic Hypertrophic Cardiomyopathy Markers
  • Lovedeep S. Dhingra, Veer Sangha, Arya Aminorroaya, Robyn Bryde, Andrew Gaballa, Adel H. Ali, Nandini Mehra, Harlan M. Krumholz, Sounok Sen, Christopher M. Kramer, Matthew W. Martinez, Milind Y. Desai, Evangelos K. Oikonomou, Rohan Khera

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.